BiotechTube

Posiphen + Placebo

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease, Parkinson Disease

Trial Timeline

Aug 14, 2020 → Jan 31, 2022

NCT ID
NCT04524351

About Posiphen + Placebo

Posiphen + Placebo is a phase 1/2 stage product being developed by Annovis Bio for Alzheimer Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04524351. Target conditions include Alzheimer Disease, Parkinson Disease.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (2)

NCT IDPhaseStatus
NCT04524351Phase 1/2Completed
NCT02925650Phase 1/2Completed

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25

Other Products from Annovis Bio

buntanetap/posiphen + PlaceboPhase 3
69
buntanetap/posiphen + PlaceboPhase 3
69
Buntanetap/Posiphen + PlaceboPhase 2/3
57
buntanetap/posiphenPhase 2/3
57
Posiphen + PlaceboPhase 1/2
33